Is JetBlue The Best Airline Stock?
Following a general trend of improvement among airline stocks, shares…
Sell
42
CRBU Quote, Financials, Valuation and Earnings
Last price:
$1.90
Seasonality move
:
-18.24%
Day range:
$1.84 - $1.90
52-week range:
$0.66 - $3.54
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
18.62x
P/B ratio:
1.23x
Volume:
719.5K
Avg. volume:
3.6M
1-year change:
-12.62%
Market cap:
$174.8M
Revenue:
$10M
EPS (TTM):
-$1.70
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CRBU
Caribou Biosciences, Inc.
|
$1.9M | -$0.40 | -8.75% | -5.26% | $11.13 |
|
DARE
Daré Bioscience, Inc.
|
-- | -$0.40 | 2911.81% | -13.48% | $10.75 |
|
MSPR
MSP Recovery
|
-- | -- | -- | -- | -- |
|
PHIO
Phio Pharmaceuticals Corp.
|
-- | -$0.44 | -- | -75.48% | $14.00 |
|
SEPN
Septerna, Inc.
|
$75M | $0.79 | 7918.87% | -80.44% | $29.25 |
|
THAR
Tharimmune, Inc.
|
-- | -- | -- | -- | $5.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CRBU
Caribou Biosciences, Inc.
|
$1.87 | $11.13 | $174.8M | -- | $0.00 | 0% | 18.62x |
|
DARE
Daré Bioscience, Inc.
|
$1.86 | $10.75 | $26.6M | 95.38x | $0.00 | 0% | 375.47x |
|
MSPR
MSP Recovery
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
PHIO
Phio Pharmaceuticals Corp.
|
$1.15 | $14.00 | $12.4M | -- | $0.00 | 0% | -- |
|
SEPN
Septerna, Inc.
|
$25.49 | $29.25 | $1.1B | 66.50x | $0.00 | 0% | 48.01x |
|
THAR
Tharimmune, Inc.
|
$2.60 | $5.00 | $91.1M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CRBU
Caribou Biosciences, Inc.
|
15.22% | 5.123 | 11.69% | 5.29x |
|
DARE
Daré Bioscience, Inc.
|
74.07% | 0.176 | 27.91% | 1.09x |
|
MSPR
MSP Recovery
|
-- | 0.000 | -- | -- |
|
PHIO
Phio Pharmaceuticals Corp.
|
-- | 2.829 | -- | 6.43x |
|
SEPN
Septerna, Inc.
|
5.84% | 4.280 | 2.87% | 6.42x |
|
THAR
Tharimmune, Inc.
|
3.08% | 2.102 | 0.96% | 4.93x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CRBU
Caribou Biosciences, Inc.
|
$1.6M | -$29.4M | -66.02% | -74.16% | -1337.58% | -$25.3M |
|
DARE
Daré Bioscience, Inc.
|
-$610.6K | -$3.7M | -459.12% | -- | -159660.87% | -$616.8K |
|
MSPR
MSP Recovery
|
-- | -- | -- | -- | -- | -- |
|
PHIO
Phio Pharmaceuticals Corp.
|
-$2K | -$2.5M | -95.19% | -95.19% | -- | -$2.1M |
|
SEPN
Septerna, Inc.
|
$21.1M | -$9.9M | -15.91% | -17.06% | -45.99% | $168.8M |
|
THAR
Tharimmune, Inc.
|
-- | -$2.1M | -462.2% | -514.29% | -- | -$1.9M |
Caribou Biosciences, Inc. vs. Competitors
-
Which has Higher Returns CRBU or DARE?
Daré Bioscience, Inc. has a net margin of -1253.32% compared to Caribou Biosciences, Inc.'s net margin of -154904.35%. Caribou Biosciences, Inc.'s return on equity of -74.16% beat Daré Bioscience, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CRBUCaribou Biosciences, Inc.71.29% -$0.30 $167.3M DAREDaré Bioscience, Inc.-26547.83% -$0.28 $11M -
What do Analysts Say About CRBU or DARE?
Caribou Biosciences, Inc. has a consensus price target of $11.13, signalling upside risk potential of 494.92%. On the other hand Daré Bioscience, Inc. has an analysts' consensus of $10.75 which suggests that it could grow by 477.96%. Given that Caribou Biosciences, Inc. has higher upside potential than Daré Bioscience, Inc., analysts believe Caribou Biosciences, Inc. is more attractive than Daré Bioscience, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CRBUCaribou Biosciences, Inc.6 1 0 DAREDaré Bioscience, Inc.3 0 0 -
Is CRBU or DARE More Risky?
Caribou Biosciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Daré Bioscience, Inc. has a beta of 0.771, suggesting its less volatile than the S&P 500 by 22.917%.
-
Which is a Better Dividend Stock CRBU or DARE?
Caribou Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Daré Bioscience, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Caribou Biosciences, Inc. pays -- of its earnings as a dividend. Daré Bioscience, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CRBU or DARE?
Caribou Biosciences, Inc. quarterly revenues are $2.2M, which are larger than Daré Bioscience, Inc. quarterly revenues of $2.3K. Caribou Biosciences, Inc.'s net income of -$27.5M is lower than Daré Bioscience, Inc.'s net income of -$3.6M. Notably, Caribou Biosciences, Inc.'s price-to-earnings ratio is -- while Daré Bioscience, Inc.'s PE ratio is 95.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Caribou Biosciences, Inc. is 18.62x versus 375.47x for Daré Bioscience, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRBUCaribou Biosciences, Inc.18.62x -- $2.2M -$27.5M DAREDaré Bioscience, Inc.375.47x 95.38x $2.3K -$3.6M
-
Which has Higher Returns CRBU or MSPR?
MSP Recovery has a net margin of -1253.32% compared to Caribou Biosciences, Inc.'s net margin of --. Caribou Biosciences, Inc.'s return on equity of -74.16% beat MSP Recovery's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CRBUCaribou Biosciences, Inc.71.29% -$0.30 $167.3M MSPRMSP Recovery-- -- -- -
What do Analysts Say About CRBU or MSPR?
Caribou Biosciences, Inc. has a consensus price target of $11.13, signalling upside risk potential of 494.92%. On the other hand MSP Recovery has an analysts' consensus of -- which suggests that it could fall by --. Given that Caribou Biosciences, Inc. has higher upside potential than MSP Recovery, analysts believe Caribou Biosciences, Inc. is more attractive than MSP Recovery.
Company Buy Ratings Hold Ratings Sell Ratings CRBUCaribou Biosciences, Inc.6 1 0 MSPRMSP Recovery0 0 0 -
Is CRBU or MSPR More Risky?
Caribou Biosciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison MSP Recovery has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock CRBU or MSPR?
Caribou Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MSP Recovery offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Caribou Biosciences, Inc. pays -- of its earnings as a dividend. MSP Recovery pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CRBU or MSPR?
Caribou Biosciences, Inc. quarterly revenues are $2.2M, which are larger than MSP Recovery quarterly revenues of --. Caribou Biosciences, Inc.'s net income of -$27.5M is higher than MSP Recovery's net income of --. Notably, Caribou Biosciences, Inc.'s price-to-earnings ratio is -- while MSP Recovery's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Caribou Biosciences, Inc. is 18.62x versus -- for MSP Recovery. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRBUCaribou Biosciences, Inc.18.62x -- $2.2M -$27.5M MSPRMSP Recovery-- -- -- --
-
Which has Higher Returns CRBU or PHIO?
Phio Pharmaceuticals Corp. has a net margin of -1253.32% compared to Caribou Biosciences, Inc.'s net margin of --. Caribou Biosciences, Inc.'s return on equity of -74.16% beat Phio Pharmaceuticals Corp.'s return on equity of -95.19%.
Company Gross Margin Earnings Per Share Invested Capital CRBUCaribou Biosciences, Inc.71.29% -$0.30 $167.3M PHIOPhio Pharmaceuticals Corp.-- -$0.44 $9.8M -
What do Analysts Say About CRBU or PHIO?
Caribou Biosciences, Inc. has a consensus price target of $11.13, signalling upside risk potential of 494.92%. On the other hand Phio Pharmaceuticals Corp. has an analysts' consensus of $14.00 which suggests that it could grow by 1117.39%. Given that Phio Pharmaceuticals Corp. has higher upside potential than Caribou Biosciences, Inc., analysts believe Phio Pharmaceuticals Corp. is more attractive than Caribou Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CRBUCaribou Biosciences, Inc.6 1 0 PHIOPhio Pharmaceuticals Corp.1 0 0 -
Is CRBU or PHIO More Risky?
Caribou Biosciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Phio Pharmaceuticals Corp. has a beta of 0.920, suggesting its less volatile than the S&P 500 by 7.968%.
-
Which is a Better Dividend Stock CRBU or PHIO?
Caribou Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Phio Pharmaceuticals Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Caribou Biosciences, Inc. pays -- of its earnings as a dividend. Phio Pharmaceuticals Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CRBU or PHIO?
Caribou Biosciences, Inc. quarterly revenues are $2.2M, which are larger than Phio Pharmaceuticals Corp. quarterly revenues of --. Caribou Biosciences, Inc.'s net income of -$27.5M is lower than Phio Pharmaceuticals Corp.'s net income of -$2.4M. Notably, Caribou Biosciences, Inc.'s price-to-earnings ratio is -- while Phio Pharmaceuticals Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Caribou Biosciences, Inc. is 18.62x versus -- for Phio Pharmaceuticals Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRBUCaribou Biosciences, Inc.18.62x -- $2.2M -$27.5M PHIOPhio Pharmaceuticals Corp.-- -- -- -$2.4M
-
Which has Higher Returns CRBU or SEPN?
Septerna, Inc. has a net margin of -1253.32% compared to Caribou Biosciences, Inc.'s net margin of 38.02%. Caribou Biosciences, Inc.'s return on equity of -74.16% beat Septerna, Inc.'s return on equity of -17.06%.
Company Gross Margin Earnings Per Share Invested Capital CRBUCaribou Biosciences, Inc.71.29% -$0.30 $167.3M SEPNSepterna, Inc.98.14% $0.18 $412.8M -
What do Analysts Say About CRBU or SEPN?
Caribou Biosciences, Inc. has a consensus price target of $11.13, signalling upside risk potential of 494.92%. On the other hand Septerna, Inc. has an analysts' consensus of $29.25 which suggests that it could grow by 14.75%. Given that Caribou Biosciences, Inc. has higher upside potential than Septerna, Inc., analysts believe Caribou Biosciences, Inc. is more attractive than Septerna, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CRBUCaribou Biosciences, Inc.6 1 0 SEPNSepterna, Inc.4 0 0 -
Is CRBU or SEPN More Risky?
Caribou Biosciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Septerna, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock CRBU or SEPN?
Caribou Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Septerna, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Caribou Biosciences, Inc. pays -- of its earnings as a dividend. Septerna, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CRBU or SEPN?
Caribou Biosciences, Inc. quarterly revenues are $2.2M, which are smaller than Septerna, Inc. quarterly revenues of $21.5M. Caribou Biosciences, Inc.'s net income of -$27.5M is lower than Septerna, Inc.'s net income of $8.2M. Notably, Caribou Biosciences, Inc.'s price-to-earnings ratio is -- while Septerna, Inc.'s PE ratio is 66.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Caribou Biosciences, Inc. is 18.62x versus 48.01x for Septerna, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRBUCaribou Biosciences, Inc.18.62x -- $2.2M -$27.5M SEPNSepterna, Inc.48.01x 66.50x $21.5M $8.2M
-
Which has Higher Returns CRBU or THAR?
Tharimmune, Inc. has a net margin of -1253.32% compared to Caribou Biosciences, Inc.'s net margin of --. Caribou Biosciences, Inc.'s return on equity of -74.16% beat Tharimmune, Inc.'s return on equity of -514.29%.
Company Gross Margin Earnings Per Share Invested Capital CRBUCaribou Biosciences, Inc.71.29% -$0.30 $167.3M THARTharimmune, Inc.-- -$0.34 $6.4M -
What do Analysts Say About CRBU or THAR?
Caribou Biosciences, Inc. has a consensus price target of $11.13, signalling upside risk potential of 494.92%. On the other hand Tharimmune, Inc. has an analysts' consensus of $5.00 which suggests that it could grow by 92.31%. Given that Caribou Biosciences, Inc. has higher upside potential than Tharimmune, Inc., analysts believe Caribou Biosciences, Inc. is more attractive than Tharimmune, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CRBUCaribou Biosciences, Inc.6 1 0 THARTharimmune, Inc.1 0 0 -
Is CRBU or THAR More Risky?
Caribou Biosciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Tharimmune, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock CRBU or THAR?
Caribou Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tharimmune, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Caribou Biosciences, Inc. pays -- of its earnings as a dividend. Tharimmune, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CRBU or THAR?
Caribou Biosciences, Inc. quarterly revenues are $2.2M, which are larger than Tharimmune, Inc. quarterly revenues of --. Caribou Biosciences, Inc.'s net income of -$27.5M is lower than Tharimmune, Inc.'s net income of -$2.1M. Notably, Caribou Biosciences, Inc.'s price-to-earnings ratio is -- while Tharimmune, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Caribou Biosciences, Inc. is 18.62x versus -- for Tharimmune, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRBUCaribou Biosciences, Inc.18.62x -- $2.2M -$27.5M THARTharimmune, Inc.-- -- -- -$2.1M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Netflix Buy Warner Bros?
Following a bidding war, Netflix (NASDAQ:NFLX) has announced its intention…
Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Stock Ideas
Buy
64
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Buy
60
OLMA alert for Dec 10
Olema Pharmaceuticals, Inc. [OLMA] is up 15.35% over the past day.
Buy
84
TSAT alert for Dec 10
Telesat Corp. [TSAT] is up 3.07% over the past day.
Buy
54
GDXU alert for Dec 10
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is up 4.83% over the past day.
